Q4 2024 GeneDx Holdings Corp Earnings Call Transcript
Key Points
- GeneDx Holdings Corp (WGS) reported fourth-quarter revenues exceeding $95 million, surpassing expectations.
- The company achieved a gross margin expansion to 70%, indicating improved operational efficiency.
- Exome and genome revenues grew 101% year-over-year, showcasing strong demand for their flagship products.
- GeneDx set a 2025 revenue guidance of $350 million to $360 million, with at least 30% growth in exome and genome volume and revenue.
- The company launched an ultra-rapid whole genome sequencing product, delivering results in as soon as 48 hours, demonstrating continued innovation.
- Nearly half of all tests are being denied, indicating challenges in reimbursement processes.
- The company is exiting the hereditary cancer segment in 2025, which may impact revenue streams.
- There is a seasonal effect in the business, with Q1 typically being the weakest quarter.
- Despite improvements, the average reimbursement rate is still below institutional Medicaid rates.
- The company anticipates a step up in operating expenses as they invest in growth and automation.
Good day and thank you for standing by. Welcome to the GeneDx fourth-quarter 2024 earnings conference call. (Operator Instructions)
I would not like to hand the comments over to your speaker today, Sabrina Dunbar, Investor Relations, please go ahead.
Thank you, Operator, and thank you to everyone for joining us today. On the call, we have Katherine Stueland, President and Chief Executive Officer; and Kevin Feeley, Chief Financial Officer. Earlier today, GeneDx released financial results for the fourth quarter ended December 31, 2024 and full year 2024.
Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today's call, including about our business plans, guidance and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, February 18, and we are under no obligation to update. When discussing our results, we refer to non-GAAP measures, which exclude certain items from reported
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
